Axogen (AXGN) Left Russell Indices, Is The Upside Already Priced In?

Axogen (AXGN) has been removed from several Russell indices, including the Russell Microcap and Russell 3000E families. This change can influence index-linked fund positioning and may prompt closer attention from existing shareholders.

See our latest analysis for Axogen.

Despite Axogen’s index removals and a 1 day share price decline of 4.7% to US$44.02, the stock still shows strong momentum, with a year to date share price return of 42% and a very large 1 year total shareholder return of 298.01%.

If the Axogen move has you rethinking growth themes in healthcare, this could be a useful moment to widen your search with 39 healthcare AI stocks

So after Axogen’s index removals and powerful recent returns, should you see today’s price as a rare discount backed by growth in peripheral nerve repair, or are markets already pricing in much of the company’s future potential?

Most Popular Narrative: 13.3% Undervalued

Against Axogen’s last close of $44.02, the most followed narrative points to a fair value of $50.78, putting a clear gap between the model and the market.

Broad-based adoption of Axogen’s nerve care algorithm across multiple markets (extremities, oral maxillofacial, breast) and exceptional momentum in activating high-potential accounts signal that the addressable market for nerve repair is still substantially underpenetrated, suggesting a long runway for sustained double-digit revenue growth as awareness and adoption rise.

Read the complete narrative.

Want to understand why this narrative sees so much headroom for Axogen? The story leans heavily on accelerating revenue, rising margins and a rich future earnings multiple. Curious which assumptions really carry the valuation and how stretched they are relative to current profits? The full narrative lays out the numbers driving that $50.78 fair value and the gap to today’s price.

Result: Fair Value of $50.78 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, Axogen’s reliance on Avance Nerve Graft and the uncertainty around the Biologics License Application process could quickly challenge this 13.3% undervalued narrative.

Find out about the key risks to this Axogen narrative.

Another View on Axogen’s Valuation

While the most popular Axogen narrative points to a fair value of $50.78 and labels the stock as 13.3% undervalued, our DCF model presents a different view. It calculates a future cash flow value of $34.47, which makes the current $44.02 share price appear expensive. Which set of assumptions do you find more realistic?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

Mixed signals around Axogen’s valuation and future potential are clear, so use this moment to look through the numbers yourself and form a view quickly. Then weigh up the 1 key reward and 2 important warning signs

Looking for more investment ideas beyond Axogen?

If Axogen has sharpened your focus on opportunities, do not stop here. Broaden your watchlist now or you will likely miss other compelling setups.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]